Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1765 entries
Sorted by: Best Match Show Resources per page
Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment.

Diabetes, metabolic syndrome and obesity : targets and therapy

Scott D.
PMID: 24124385
Diabetes Metab Syndr Obes. 2013 Oct 02;6:359-63. doi: 10.2147/DMSO.S51795. eCollection 2013.

Diabetes is the leading cause of chronic kidney disease, and the prevalence of both diseases is rising worldwide. Treatment of type 2 diabetes is difficult in patients with chronic kidney disease because most oral antidiabetic agents are affected by...

Cite
Scott D. Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment. Diabetes Metab Syndr Obes. 2013;6:359-63doi: 10.2147/DMSO.S51795.
Scott, D. (2013). Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment. Diabetes, metabolic syndrome and obesity : targets and therapy, 6359-63. https://doi.org/10.2147/DMSO.S51795
Scott, David. "Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 6 (2013): 359-63. doi: https://doi.org/10.2147/DMSO.S51795
Scott D. Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment. Diabetes Metab Syndr Obes. 2013 Oct 02;6:359-63. doi: 10.2147/DMSO.S51795. eCollection 2013. PMID: 24124385; PMCID: PMC3795009.
Copy Download .nbib Format: NLM
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy

Rigato M, Fadini GP.
PMID: 24672252
Diabetes Metab Syndr Obes. 2014 Mar 18;7:107-20. doi: 10.2147/DMSO.S37644. eCollection 2014.

Type 2 diabetes is characterized by a progressive decline in beta cell function, with consequent worsening of glycemic control. The ideal antihyperglycemic treatment should achieve good and sustained glycemic control, with a low risk of hypoglycemia and no weight...

Cite
Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014;7:107-20doi: 10.2147/DMSO.S37644.
Rigato, M., & Fadini, G. P. (2014). Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 7107-20. https://doi.org/10.2147/DMSO.S37644
Rigato, Mauro, and Fadini, Gian Paolo. "Comparative effectiveness of liraglutide in the treatment of type 2 diabetes." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 7 (2014): 107-20. doi: https://doi.org/10.2147/DMSO.S37644
Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014 Mar 18;7:107-20. doi: 10.2147/DMSO.S37644. eCollection 2014. PMID: 24672252; PMCID: PMC3964023.
Copy Download .nbib Format: NLM
Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine.

Diabetes, metabolic syndrome and obesity : targets and therapy

Ogedengbe OS, Ezeani IU, Chukwuonye II, Anyabolu EN, Ozor II, Eregie A.
PMID: 26396537
Diabetes Metab Syndr Obes. 2015 Sep 18;8:437-45. doi: 10.2147/DMSO.S69199. eCollection 2015.

BACKGROUND: The aim of this study is to evaluate the impact of coexistence of metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) on the estimated cardiovascular risk as calculated using the United Kingdom Prospective Diabetic Study risk engine...

Cite
Ogedengbe OS, Ezeani IU, Chukwuonye II, et al. Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine. Diabetes Metab Syndr Obes. 2015;8:437-45doi: 10.2147/DMSO.S69199.
Ogedengbe, O. S., Ezeani, I. U., Chukwuonye, I. I., Anyabolu, E. N., Ozor, I. I., & Eregie, A. (2015). Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine. Diabetes, metabolic syndrome and obesity : targets and therapy, 8437-45. https://doi.org/10.2147/DMSO.S69199
Ogedengbe, O Stephen, et al. "Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 8 (2015): 437-45. doi: https://doi.org/10.2147/DMSO.S69199
Ogedengbe OS, Ezeani IU, Chukwuonye II, Anyabolu EN, Ozor II, Eregie A. Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in persons with metabolic syndrome using the UKPDS risk engine. Diabetes Metab Syndr Obes. 2015 Sep 18;8:437-45. doi: 10.2147/DMSO.S69199. eCollection 2015. PMID: 26396537; PMCID: PMC4577267.
Copy Download .nbib Format: NLM
An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting.

Diabetes, metabolic syndrome and obesity : targets and therapy

Courtney MR, Moler EJ, Osborne JA, Whitney G, Conard SE.
PMID: 26425102
Diabetes Metab Syndr Obes. 2015 Sep 18;8:447-53. doi: 10.2147/DMSO.S78810. eCollection 2015.

BACKGROUND: Primary care providers with limited time and resources bear a heavy responsibility for chronic disease prevention or progression. Reliable clinical tools are needed to risk stratify patients for more targeted care. This exploratory study examined the care of...

Cite
Courtney MR, Moler EJ, Osborne JA, et al. An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting. Diabetes Metab Syndr Obes. 2015;8:447-53doi: 10.2147/DMSO.S78810.
Courtney, M. R., Moler, E. J., Osborne, J. A., Whitney, G., & Conard, S. E. (2015). An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting. Diabetes, metabolic syndrome and obesity : targets and therapy, 8447-53. https://doi.org/10.2147/DMSO.S78810
Courtney, Maureen R, et al. "An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 8 (2015): 447-53. doi: https://doi.org/10.2147/DMSO.S78810
Courtney MR, Moler EJ, Osborne JA, Whitney G, Conard SE. An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting. Diabetes Metab Syndr Obes. 2015 Sep 18;8:447-53. doi: 10.2147/DMSO.S78810. eCollection 2015. PMID: 26425102; PMCID: PMC4583107.
Copy Download .nbib Format: NLM
Clinical utility of metabolic syndrome severity scores: considerations for practitioners.

Diabetes, metabolic syndrome and obesity : targets and therapy

DeBoer MD, Gurka MJ.
PMID: 28255250
Diabetes Metab Syndr Obes. 2017 Feb 20;10:65-72. doi: 10.2147/DMSO.S101624. eCollection 2017.

The metabolic syndrome (MetS) is marked by abnormalities in central obesity, high blood pressure, high triglycerides, low high-density lipoprotein-cholesterol, and high fasting glucose and appears to be produced by underlying processes of inflammation, oxidative stress, and adipocyte dysfunction. MetS...

Cite
DeBoer MD, Gurka MJ. Clinical utility of metabolic syndrome severity scores: considerations for practitioners. Diabetes Metab Syndr Obes. 2017;10:65-72doi: 10.2147/DMSO.S101624.
DeBoer, M. D., & Gurka, M. J. (2017). Clinical utility of metabolic syndrome severity scores: considerations for practitioners. Diabetes, metabolic syndrome and obesity : targets and therapy, 1065-72. https://doi.org/10.2147/DMSO.S101624
DeBoer, Mark D, and Gurka, Matthew J. "Clinical utility of metabolic syndrome severity scores: considerations for practitioners." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 65-72. doi: https://doi.org/10.2147/DMSO.S101624
DeBoer MD, Gurka MJ. Clinical utility of metabolic syndrome severity scores: considerations for practitioners. Diabetes Metab Syndr Obes. 2017 Feb 20;10:65-72. doi: 10.2147/DMSO.S101624. eCollection 2017. PMID: 28255250; PMCID: PMC5325095.
Copy Download .nbib Format: NLM
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy

Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A.
PMID: 25759591
Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. doi: 10.2147/DMSO.S76342. eCollection 2015.

PURPOSE: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2...

Cite
Powell DR, Doree D, Jeter-Jones S, et al. Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes Metab Syndr Obes. 2015;8:121-7doi: 10.2147/DMSO.S76342.
Powell, D. R., Doree, D., Jeter-Jones, S., Ding, Z. M., Zambrowicz, B., & Sands, A. (2015). Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 8121-7. https://doi.org/10.2147/DMSO.S76342
Powell, David R, et al. "Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 8 (2015): 121-7. doi: https://doi.org/10.2147/DMSO.S76342
Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A. Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. doi: 10.2147/DMSO.S76342. eCollection 2015. PMID: 25759591; PMCID: PMC4346285.
Copy Download .nbib Format: NLM
Factors affecting high-sensitivity cardiac troponin T elevation in Japanese metabolic syndrome patients.

Diabetes, metabolic syndrome and obesity : targets and therapy

Hitsumoto T, Shirai K.
PMID: 25792848
Diabetes Metab Syndr Obes. 2015 Mar 10;8:157-62. doi: 10.2147/DMSO.S80907. eCollection 2015.

PURPOSE: The blood concentration of cardiac troponin T (ie, high-sensitivity cardiac troponin T [hs-cTnT]), measured using a highly sensitive assay, represents a useful biomarker for evaluating the pathogenesis of heart failure or predicting cardiovascular events. However, little is known...

Cite
Hitsumoto T, Shirai K. Factors affecting high-sensitivity cardiac troponin T elevation in Japanese metabolic syndrome patients. Diabetes Metab Syndr Obes. 2015;8:157-62doi: 10.2147/DMSO.S80907.
Hitsumoto, T., & Shirai, K. (2015). Factors affecting high-sensitivity cardiac troponin T elevation in Japanese metabolic syndrome patients. Diabetes, metabolic syndrome and obesity : targets and therapy, 8157-62. https://doi.org/10.2147/DMSO.S80907
Hitsumoto, Takashi, and Shirai, Kohji. "Factors affecting high-sensitivity cardiac troponin T elevation in Japanese metabolic syndrome patients." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 8 (2015): 157-62. doi: https://doi.org/10.2147/DMSO.S80907
Hitsumoto T, Shirai K. Factors affecting high-sensitivity cardiac troponin T elevation in Japanese metabolic syndrome patients. Diabetes Metab Syndr Obes. 2015 Mar 10;8:157-62. doi: 10.2147/DMSO.S80907. eCollection 2015. PMID: 25792848; PMCID: PMC4362654.
Copy Download .nbib Format: NLM
Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol(®) on glycemic control of subjects with impaired fasting glucose.

Diabetes, metabolic syndrome and obesity : targets and therapy

Evans M, Judy WV, Wilson D, Rumberger JA, Guthrie N.
PMID: 26150732
Diabetes Metab Syndr Obes. 2015 Jun 25;8:275-86. doi: 10.2147/DMSO.S79450. eCollection 2015.

BACKGROUND: This study investigated the efficacy of Diabetinol(®) in people with diabetes on medication but not meeting the American Association of Clinical Endocrinologists and American Diabetes Association glycemic, blood pressure, and lipid targets.SUBJECTS AND METHODS: Fifty subjects, aged 18-75...

Cite
Evans M, Judy WV, Wilson D, et al. Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol(®) on glycemic control of subjects with impaired fasting glucose. Diabetes Metab Syndr Obes. 2015;8:275-86doi: 10.2147/DMSO.S79450.
Evans, M., Judy, W. V., Wilson, D., Rumberger, J. A., & Guthrie, N. (2015). Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol(®) on glycemic control of subjects with impaired fasting glucose. Diabetes, metabolic syndrome and obesity : targets and therapy, 8275-86. https://doi.org/10.2147/DMSO.S79450
Evans, Malkanthi, et al. "Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol(®) on glycemic control of subjects with impaired fasting glucose." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 8 (2015): 275-86. doi: https://doi.org/10.2147/DMSO.S79450
Evans M, Judy WV, Wilson D, Rumberger JA, Guthrie N. Randomized, double-blind, placebo-controlled, clinical study on the effect of Diabetinol(®) on glycemic control of subjects with impaired fasting glucose. Diabetes Metab Syndr Obes. 2015 Jun 25;8:275-86. doi: 10.2147/DMSO.S79450. eCollection 2015. PMID: 26150732; PMCID: PMC4485843.
Copy Download .nbib Format: NLM
Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients.

Diabetes, metabolic syndrome and obesity : targets and therapy

Cadegiani FA, Silva OS.
PMID: 27994477
Diabetes Metab Syndr Obes. 2016 Dec 07;9:443-446. doi: 10.2147/DMSO.S123244. eCollection 2016.

OBJECTIVE: Acarbose is a glucosidase inhibitor that slows carbohydrate digestion. It could thus be effective to promote remission of dumping syndrome (DS). Previous studies associating acarbose and late dumping, although not early dumping, have been reported. Herein, we aimed...

Cite
Cadegiani FA, Silva OS. Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. Diabetes Metab Syndr Obes. 2016;9:443-446doi: 10.2147/DMSO.S123244.
Cadegiani, F. A., & Silva, O. S. (2016). Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. Diabetes, metabolic syndrome and obesity : targets and therapy, 9443-446. https://doi.org/10.2147/DMSO.S123244
Cadegiani, Flavio A, and Silva, Osvalmir Sá. "Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 9 (2016): 443-446. doi: https://doi.org/10.2147/DMSO.S123244
Cadegiani FA, Silva OS. Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. Diabetes Metab Syndr Obes. 2016 Dec 07;9:443-446. doi: 10.2147/DMSO.S123244. eCollection 2016. PMID: 27994477; PMCID: PMC5153290.
Copy Download .nbib Format: NLM
Weight loss medications in Canada - a new frontier or a repeat of past mistakes?.

Diabetes, metabolic syndrome and obesity : targets and therapy

Wharton S, Lee J, Christensen RA.
PMID: 29042804
Diabetes Metab Syndr Obes. 2017 Oct 04;10:413-417. doi: 10.2147/DMSO.S141571. eCollection 2017.

Current methods for the treatment of excess weight can involve healthy behavior changes, pharmacotherapy, and surgical interventions. Many individuals are able to lose some degree of weight through behavioral changes; however, they are often unable to maintain their weight...

Cite
Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes Metab Syndr Obes. 2017;10:413-417doi: 10.2147/DMSO.S141571.
Wharton, S., Lee, J., & Christensen, R. A. (2017). Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes, metabolic syndrome and obesity : targets and therapy, 10413-417. https://doi.org/10.2147/DMSO.S141571
Wharton, Sean, et al. "Weight loss medications in Canada - a new frontier or a repeat of past mistakes?." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 413-417. doi: https://doi.org/10.2147/DMSO.S141571
Wharton S, Lee J, Christensen RA. Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. Diabetes Metab Syndr Obes. 2017 Oct 04;10:413-417. doi: 10.2147/DMSO.S141571. eCollection 2017. PMID: 29042804; PMCID: PMC5633321.
Copy Download .nbib Format: NLM
Randomized trial of amino acid mixture combined with physical activity promotion for abdominal fat reduction in overweight adults.

Diabetes, metabolic syndrome and obesity : targets and therapy

Ueda K, Sasai H, Tsujimoto T, Sanbongi C, Ikegami S, Kobayashi H, Shioya N, Suzuki S, Nakata Y.
PMID: 29520158
Diabetes Metab Syndr Obes. 2018 Feb 26;11:23-33. doi: 10.2147/DMSO.S153151. eCollection 2018.

PURPOSE: The purpose of this study was to test the efficacy of arginine, alanine, and phenylalanine mixture (A-mix) ingestion at 1,500 mg/day in combination with the promotion of physical activity for abdominal fat reduction in overweight adults.METHODS: A placebo-controlled,...

Cite
Ueda K, Sasai H, Tsujimoto T, et al. Randomized trial of amino acid mixture combined with physical activity promotion for abdominal fat reduction in overweight adults. Diabetes Metab Syndr Obes. 2018;11:23-33doi: 10.2147/DMSO.S153151.
Ueda, K., Sasai, H., Tsujimoto, T., Sanbongi, C., Ikegami, S., Kobayashi, H., Shioya, N., Suzuki, S., & Nakata, Y. (2018). Randomized trial of amino acid mixture combined with physical activity promotion for abdominal fat reduction in overweight adults. Diabetes, metabolic syndrome and obesity : targets and therapy, 1123-33. https://doi.org/10.2147/DMSO.S153151
Ueda, Keisuke, et al. "Randomized trial of amino acid mixture combined with physical activity promotion for abdominal fat reduction in overweight adults." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 11 (2018): 23-33. doi: https://doi.org/10.2147/DMSO.S153151
Ueda K, Sasai H, Tsujimoto T, Sanbongi C, Ikegami S, Kobayashi H, Shioya N, Suzuki S, Nakata Y. Randomized trial of amino acid mixture combined with physical activity promotion for abdominal fat reduction in overweight adults. Diabetes Metab Syndr Obes. 2018 Feb 26;11:23-33. doi: 10.2147/DMSO.S153151. eCollection 2018. PMID: 29520158; PMCID: PMC5833794.
Copy Download .nbib Format: NLM
Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges.

Diabetes, metabolic syndrome and obesity : targets and therapy

Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P.
PMID: 29066925
Diabetes Metab Syndr Obes. 2017 Sep 13;10:375-383. doi: 10.2147/DMSO.S130810. eCollection 2017.

BACKGROUND: Lipodystrophy (LD; non-human immunodeficiency virus [HIV]-associated) syndromes are a rare body of disorders for which true prevalence is unknown. Prevalence estimates of rare diseases are important to increase awareness and financial resources. Current qualitative and quantitative estimates of...

Cite
Chiquette E, Oral EA, Garg A, et al. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017;10:375-383doi: 10.2147/DMSO.S130810.
Chiquette, E., Oral, E. A., Garg, A., Araújo-Vilar, D., & Dhankhar, P. (2017). Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes, metabolic syndrome and obesity : targets and therapy, 10375-383. https://doi.org/10.2147/DMSO.S130810
Chiquette, Elaine, et al. "Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 10 (2017): 375-383. doi: https://doi.org/10.2147/DMSO.S130810
Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017 Sep 13;10:375-383. doi: 10.2147/DMSO.S130810. eCollection 2017. PMID: 29066925; PMCID: PMC5604558.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1765 entries